Clinical trials: Infusion Test
Iron Deficiency Anemia (IDA)
A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia
The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established…
- Trial name
- NCT07687784
- Testing
- Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®]
- Where
- 13 sites in United States, Bulgaria and 2 more
- Volunteers
- 1,366 people
- Sponsor
- AFT Pharmaceuticals, Ltd.
Healthy Adult Subjects
A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product
To assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan.
- Trial name
- NCT02444507
- Testing
- Nexium powder for injection and infusion 40 mg, Esomelone Powder for Solution for Injection / Infusion 40 mg
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- isRed Pharma & Biotech Research Corporation
Diabetes Mellitus, Type 2
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump.
- Trial name
- NCT07068295
- Testing
- NNC0471-0119 H, Insulin Aspart
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Parkinson Disease, Movement Disorders
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS).
- Conditions
- Parkinson Disease, Movement Disorders, Neurodegenerative Diseases, Nervous System Diseases
- Trial name
- NCT03295786
- Testing
- Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 17 people
- Sponsor
- Herantis Pharma Plc.
Healthy
A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.
- Trial name
- NCT05075772
- Testing
- BI 765080
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B)…
- Trial name
- NCT05518708
- Testing
- BI 3032950
- Where
- Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Stroke, Ischemic Stroke
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the…
- Conditions
- Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
- Trial name
- NCT01273337
- Testing
- ALD-401
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aldagen
Diabetes Mellitus, Type 1
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
The study is looking at the effect and safety of a new fast-acting insulin (NNC0471 0119) to people with type 1 diabetes when given by an insulin pump.
- Trial name
- NCT06809621
- Testing
- NNC0471-0119 H, Insulin aspart
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses of BI 765250.
- Trial name
- NCT05151653
- Testing
- BI 765250
- Where
- Belgium
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.
- Trial name
- NCT01464099
- Testing
- insulin aspart
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Myocardial Infarction
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack.
- Trial name
- IRI-EXPLORE (NCT06139328)
- Testing
- BI 765845
- Where
- 53 sites in Australia, Canada and 12 more
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Healthy
Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers
The study will compare the pharmacokinetics (PK), safety and tolerability of long-term infusion of lyophilized landiolol (LDLL600) against esmolol (Brevibloc) by measurement of blood concentrations of landiolol, esmolol and their…
- Trial name
- NCT01741519
- Testing
- LDLL600, Brevibloc
- Where
- Czechia
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AOP Orphan Pharmaceuticals AG
Gastrointestinal Cancer, Lung Cancer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
This is a study in adults from Asia with different types of advanced cancer (solid tumours). People can join the study if they have cancer of the stomach, large bowel and rectum, pancreas, liver, head and neck or non-small cell…
- Conditions
- Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06091930
- Testing
- BI 765049, Ezabenlimab
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Leukaemia
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Primary Objective: Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in participants with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic…
- Trial name
- NCT03594955
- Testing
- SAR440234
- Where
- 4 sites in United States, France
- Volunteers
- 7 people
- Sponsor
- Sanofi
Parkinson's Disease
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant…
- Trial name
- NCT02096601
- Testing
- LD/CD SC solution, Entacapone
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- NeuroDerm Ltd.
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with…
- Conditions
- Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
- Trial name
- NCT06682988
- Testing
- Mirvetuximab Soravtansine
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
Neoplasms
Investigation of Mass Balance of the Test Drug and Major Metabolites
The purpose of this study is to: a) Determine how the body takes up the test drug and distributes it into various body organs and tissues, how it processes the drug and how it ultimately removes it; and b) Examine how well the…
- Trial name
- NCT00432302
- Testing
- Sagopilone (BAY 86-5302, ZK 219477)
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bayer
Small Cell Lung Carcinoma (SCLC)
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1)…
- Trial name
- DAREONᵀᴹ-8 (NCT06077500)
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Type1diabetes
CGMIS 48-hour Feasibility Study
This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.
- Trial name
- NCT05562206
- Testing
- CGMIS (Continuous Glucose Monitoring Infusion Set)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pacific Diabetes Technologies